If these new findings are confirmed, it may be eventually possible to detect mesothelioma cancer via a simple and non invasive blood test.
Bolton, UK (PRWEB UK) 4 December 2013
The study has been published in the Clinical Proteomics Journal, on the 8th of November, by an international team of researchers, led by Ferdinando Cerciello and Bernd Wollscheid, from the Institute of Molecular Systems Biology, in Zurich. (1)
The team used Selected Reaction Monitoring (SRM) technology to uncover a “signature” group of mesothelioma proteins. As reported in the results paragraph of the study, the researchers stated:
“Our evaluation of 51 candidate biomarkers in the context of a training and an independent validation set revealed a reproducible glycopeptide signature of MPM in serum which complemented the MPM biomarker mesothelin.” (1)
The SRM Test is based on the hypothesis that tumour-cells are prone to release certain glycoproteins into the circulatory system. After screening the surface of mesothelioma cell lines for potential candidate biomarkers, the team of researchers designed a test that would scan for the specific protein, which can be found in human serum. (1)
Concluding the study, the authors stated:
“Our study shows that SRM assay technology enables the direct clinical evaluation of protein-derived candidate biomarker panels for which clinically reliable ELISA’s currently do not exist.” (1)
According to the latest statistics, made available by HSE (Health and Safety Executive), the annual number of mesothelioma deaths is expected to increase in future years, peaking towards the end of this decade. (2)
Mesothelioma is a form of cancer, caused mostly through the inhalation, and retention of asbestos fibres. Unfortunately, symptoms may not appear until 50 years after the exposure, by which point, the damage will already have been done. If these new findings are confirmed, it may be eventually possible to detect mesothelioma cancer via a simple and non invasive blood test.
Asons Solicitors have a dedicated team of industrial disease specialists, dealing with cases of asbestos related diseases, giving people legal advice, particularly in the area of mesothelioma claims, and asbestos claims.
Exposure to asbestos can be deadly, and Asons urge anyone who feels they may have been exposed to asbestos fibres to consult their GP immediately for a consultation, and contact an industrial disease specialist for legal representation. To find out more information on asbestos claims, and mesothelioma compensation, contact Asons at http://www.asons.co.uk or phone 01204 521 133.
(1) Clinical Proteomics Journal - Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. clinicalproteomicsjournal.com/content/10/1/16
(2) HSE – Mesothelioma - hse.gov.uk/statistics/causdis/mesothelioma/
About Asons Solicitors:
Asons Solicitors is a Bolton-based law practice that specialises in personal injury and industrial disease claims. Founded by brothers Imran Akram and Kamran Akram, Asons Solicitors has developed to become a young and dynamic law firm that delivers practical solutions to clients in times of difficulty. Their continued focus on their staff has seen them awarded with the Investors in People “Gold Award”; which is reflected in the professional and personable approach they take in working with clients. They strive to grow and to develop, and their supportiveness and attention to detail ensures that their clients use them time and again.
For further information contact: